• Evolutionary Perspectives
• 42 min
  1. Antibiotic resistance: a mechanistic overview

  • Dr. Neil Woodford
• 20 min
  2. Mutation

  • Prof. Stephen Gillespie
• 11 min
  3. Fitness in antibiotic resistant bacteria

  • Prof. Stephen Gillespie
• 34 min
  4. Fitness and compensation

  • Dr. Sébastian Gagneux
• 22 min
  5. Antibiotic resistance and the supragenome hypothesis

  • Dr. Bambos Charalambous
• Epidemiology and Clinical Impact
• 37 min
  6. Methicillin resistant S. aureus and other resistances

  • Prof. Mark Enright
• 43 min
  7. Risk factors for antibiotic resistance in Streptococcus pneumoniae

  • Prof. Keith Klugman
• 38 min
  8. Beta-lactamases: clinical impact and epidemiology

  • Prof. Sebastian Amyes
• 49 min
  9. Glycopeptide-resistant enterococci

  • Dr. Neil Woodford
• 33 min
  10. Drug resistant tuberculosis: biology, epidemiology and control

  • Dr. Christopher Dye
• 26 min
  11. Antiretroviral drug resistance

  • Prof. Deenan Pillay
• 49 min
  12. Malaria - changing paradigms

  • Dr. Janet Cox-Singh
• 42 min
  13. Advances in mode of action of antimalarials and resistance mechanisms 1

  • Prof. David Warhurst
• 38 min
  14. Advances in mode of action of antimalarials and resistance mechanisms 2

  • Prof. David Warhurst
• Diagnosis and Surveillance of Resistance
• 29 min
  15. Conventional and automated diagnostic methods

  • Dr. Alan Johnson
• 38 min
  16. National and international surveillance of antibiotic resistance 1

  • Prof. David Livermore
• 50 min
  17. National and international surveillance of antibiotic resistance 2

  • Prof. David Livermore
• Controlling Antibiotic Resistance
• 39 min
  18. Controlling antibiotic resistance in the hospital environment

  • Dr. Ian Eltringham
• 27 min
  19. Controlling antibiotic resistance in the community

  • Dr. Peter Wilson
• 51 min
  20. Public policy to reduce antibiotic resistance

  • Dr. Niels Frimodt-Møller
• The Antibiotic Resistance Future
• 26 min
  21. Overcoming resistance through novel drug targets

  • Prof. Anthony Coates
• 37 min
  22. Medicinal chemistry strategies in combating antibiotic resistance

  • Dr. Geoffrey Coxon
• 36 min
  23. Teixobactin kills pathogens without detectable resistance

  • Prof. Kim Lewis
• Archived Lectures *These may not cover the latest advances in the field
• 48 min
  24. Molecular diagnosis of antibiotic resistance

  • Dr. Tim McHugh
• 36 min
  25. Introduction to malaria

  • Prof. David Warhurst

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Antibiotic resistance in hospitals
3. Antibiotic resistance in the community
4. The pre-antibiotic era
5. The first antibiotics
6. Penicillin (1)
7. Penicillin (2)
8. Penicillin - structure
9. Tuberculosis
10. Streptomycin
11. Trials of streptomycin
12. Streptococcus pneumoniae (1)
13. Streptococcus pneumoniae (2)
14. Multidrug resistant pneumococci
15. Multidrug resistant clones
16. Staphylococcus aureus
17. S. aureus disease
18. Spread of MRSA
19. MRSA bacteraemia as % in blood cultures
20. European distribution of MRSA
21. Increasing resistance
22. Worldwide MRSA prevalence
23. Treatment of MRSA
24. The benefits of antibiotics
25. The extent of resistance in the UK
26. Causes of resistance - mutation
27. Causes of resistance - gene transfer
28. Increased use leads to more resistance
29. Antibiotic classes - beta-lactams
30. Antibiotic classes - glycopeptides
31. Antibiotic classes - Aminoglycosides
32. Antibiotic classes - Fluoroquinolones
33. Antibiotic classes - Macrolides
34. Antibiotic classes- trimethoprim and tetracyclines
35. Other antibiotic classes
36. Antibiotic agents in the community and hospitals
37. Antimicrobial use and selection for resistance
38. The threat
39. Implications of inappropriate antibacterial therapy
40. Why no new antibiotics?

Topics Covered

• Antibiotic resistance in hospitals
• Antibiotic resistance in the community
• The pre-antibiotic era
• Penicillin
• Tuberculosis
• Streptomycin
• Streptococcus pneumoniae
• Multidrug resistant pneumococci
• Staphylococcus aureus
• Spread of MRSA
• European and worldwide distribution of MRSA
• Treatment of MRSA
• The benefits of antibiotics
• The extent of bacterial resistance in the UK
• Causes of resistance
• Antibiotic classes
• The pyramids for antimicrobial use and selection for antimicrobial resistance
• The threat
• Why no new antibiotics?

Links

Series:

• Antibiotic Resistance

Categories:

• Clinical Practice
• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases

Talk Citation

Publication History

• Published on December 31, 2009

Financial Disclosures

• Prof. Mark Enright has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.